A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR Sublingual Immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Trial Profile

A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III study to assess the long term efficacy, carry-over effect and safety of two dosing regimens of 300 IR Sublingual Immunotherapy (SLIT) administered as allergen-based tablets once daily to patients suffering from grass pollen rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Grass pollen allergy immunotherapy (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Stallergenes SA
  • Most Recent Events

    • 07 Mar 2016 Pooled analysis of 4 trials (n=891), including this study and 3 other studies [see CTP 700020053, 700039691, 700040181] was presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Sep 2012 Results from an analysis of asthma status on outcomes presented at the 22nd Annual Congress of the European Respiratory Society.
    • 21 Jun 2012 Planned number of patients changed from 630 to 780 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top